Hoth Therapeutics, Inc. (HOTH) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 2.65M | 2.61M | 4.08M | 2.2M | 3.48M | 2.38M | 2.13M | 1.65M | 2.16M | 1.7M | 2.09M | 1.71M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.13M | 1.29M | 2.45M | 1.16M | 1.52M | 1.06M | 1.23M | 1.08M | 1.59M | 783.22K | 1.12M | 1.06M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.52M | 1.31M | 1.63M | 1.04M | 1.96M | 1.32M | 897.51K | 566.34K | 571.64K | 914.6K | 974.37K | 652.2K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.65M | -2.61M | -4.08M | -2.2M | -3.48M | -2.38M | -2.13M | -1.65M | -2.16M | -1.7M | -2.09M | -1.71M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 23.81% | -9.31% | -91.38% | -33.65% | -60.93% | -40.37% | -1.88% | 3.67% | 1.5% | 50.37% | 22.03% | 25.7% |
| EBITDA | -2.69M | -2.69M | -4.11M | -2.2M | 0 | 0 | -2.13M | -1.63M | 0 | -1.7M | 0 | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -92.58% | -34.73% | - | 100% | - | - | - | 51.06% | - | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 3.48M | 2.38M | 0 | 0 | 2.16M | 0 | 2.09M | 1.71M |
| EBIT | -2.69M | -2.69M | -4.11M | -2.2M | -3.48M | -2.38M | -2.13M | -1.63M | -2.15M | -1.7M | -2.09M | -1.87M |
| Net Interest Income | 0 | 158 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.56K | 0 | 2 |
| Interest Income | 0 | 158 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 751 | 0 | 2 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.31K | 0 | 0 |
| Other Income/Expense | -44.02K | -83.17K | -25.14K | 173 | 181 | 192 | 200 | 13.37K | 13.38K | -4.45K | 6.4K | -164.4K |
| Pretax Income | -2.69M | -2.69M | -4.11M | -2.2M | -3.48M | -2.38M | -2.13M | -1.63M | -2.15M | -1.7M | -2.09M | -1.87M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.69M | -2.69M | -4.11M | -2.2M | -3.48M | -2.38M | -2.13M | -1.63M | -2.15M | -1.7M | -2.09M | -1.87M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 22.54% | -12.81% | -92.58% | -34.73% | -61.93% | -39.99% | -2.18% | 12.84% | 1.69% | 51.06% | 21.09% | 30.05% |
| Net Income (Continuing) | -2.69M | -2.69M | -4.11M | -2.2M | -3.48M | -2.38M | -2.13M | -1.63M | -2.15M | -1.7M | -2.09M | -1.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.17 | -0.17 | -0.30 | -0.17 | -0.36 | -0.33 | -0.31 | -0.24 | -0.46 | -0.39 | -0.60 | -0.57 |
| EPS Growth % | 52.78% | 48.48% | 3.23% | 29.17% | 21.74% | 15.38% | 48.33% | 57.89% | 47.73% | 87.77% | 70.3% | 73.61% |
| EPS (Basic) | -0.17 | -0.17 | -0.30 | -0.17 | -0.36 | -0.33 | -0.31 | -0.24 | -0.46 | -0.39 | -0.60 | -0.57 |
| Diluted Shares Outstanding | 15.79M | 15.51M | 13.79M | 13.18M | 9.78M | 7.29M | 6.9M | 6.88M | 4.4M | 4.35M | 3.48M | 3.3M |
| Basic Shares Outstanding | 15.79M | 15.51M | 13.79M | 13.18M | 9.78M | 7.29M | 6.9M | 6.88M | 4.4M | 4.35M | 3.48M | 3.3M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |